Pipemidic acid
(Synonyms: 吡哌酸) 目录号 : GC33935
An antibiotic
Cas No.:51940-44-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Pipemidic acid is an antibiotic and derivative of piromidic acid .1 It is active against clinical isolates of E. coli, P. mirabilis, P. inconstans, Shigella, Salmonella, Alcaligenes, and V. parahaemolyticus (MICs = 0.78-100 ?g/ml), as well as drug-resistant clinical isolates of E. coli, P. mirabilis, Klebsiella, and Shigella (MICs = 1.56-6.25 ?g/ml). Pipemidic acid is protective against systemic S. aureus, E. coli, K. pneumoniae, and P. aeruginosa infections in mice (ED50s = 237.5, 204.1, 28.6, and 99.5 mg/kg, respectively).2 It is also protective against P. aeruginosa-induced pulmonary and dermal infections (ED50s = 81.7 and 173.2 mg/kg, respectively), as well as E. coli, K. pneumoniae, and P. aeruginosa urinary bladder infections (ED50s = 4.8, 11.9, and 30.6 mg/kg, respectively), in mice.
1.Shimizu, Y., Takase, Y., Nakamura, S., et al.Pipemidic acid, a new antibacterial agent active against Pseudomonas aeruginosa: In vitro propertiesAntimicrob. Agents Chemother.8(2)132-138(1975) 2.Shimizu, M., Takdase, Y., Nakamura, S., et al.Pipemidic acid: Its activities against various experimental infectionsAntimicrob. Agents Chemother.9(4)569-574(1976)
| Cas No. | 51940-44-4 | SDF | |
| 别名 | 吡哌酸 | ||
| Canonical SMILES | O=C(C1=CN(CC)C2=NC(N3CCNCC3)=NC=C2C1=O)O | ||
| 分子式 | C14H17N5O3 | 分子量 | 303.32 |
| 溶解度 | DMSO : 5.45 mg/mL (17.97 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.2968 mL | 16.4842 mL | 32.9685 mL |
| 5 mM | 0.6594 mL | 3.2968 mL | 6.5937 mL |
| 10 mM | 0.3297 mL | 1.6484 mL | 3.2968 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Pipemidic acid: absorption, distribution, and excretion
Antimicrob Agents Chemother 1975 Apr;7(4):441-6.PMID:1147580DOI:10.1128/AAC.7.4.441.
Pipemidic acid was absorbed well by the oral route. Its peak levels in plasma ranged from 4 to 12 mug/ml at an oral dose of about 50 mg/kg in mice, rats, dogs, monkeys, and men. The protein binding of Pipemidic acid was about 20% in dog plasma and about 30% in human serum. Pipemidic acid was distributed to most of the organs and tissues tested at the concentrations comparable to or higher than the plasma level. Its concentrations in bile and urine were much higher than the plasma level. About 25 to 88% of orally administered Pipemidic acid was excreted into urine in a bacteriologically active form, the percentage depending on the animals and doses employed. The remainder was excreted into feces in men. The main active principle in vivo was unchanged Pipemidic acid itself. The mean lethal dose of Pipemidic acid after a single oral dose was more than 16,000 mg/kg in mice. No abnormalities were observed in mice orally receiving Pipemidic acid once a day for 4 weeks at doses of 1,000, 2,000, and 4,000 mg/kg per day, and in rats orally receiving the drug once a day for 2 weeks at doses of 400 and 1,600 mg/kg per day.
Pipemidic acid: its activities against various experimental infections
Antimicrob Agents Chemother 1976 Apr;9(4):569-74.PMID:1267435DOI:10.1128/AAC.9.4.569.
Pipemidic acid, a structural relative of piromidic and nalidixic acids, exhibited substantial therapeutic activity when it was administered orally to mice bearing either widely disseminated or relatively localized infections with Staphylococcus aureus and a variety of gram-negative bacilli. The activity of Pipemidic acid was always greater than that of piromidic and nalidixic acids; in infections with Pseudomonas aeruginosa and in bacilli resistant to the latter two drugs, Pipemidic acid exhibited significant activity. In limited comparative studies, the activities of Pipemidic acid were generally superior to the activities of cephalexin, ampicillin, and carbenicillin. Gentamicin, administered subcutaneously, was more active than Pipemidic acid, given either orally or subcutaneously, against both systemic and localized infections with P. aeruginosa. The therapeutic accomplishments of Pipemidic acid were attained with well-tolerated doses.
Pipemidic acid, a new antibacterial agent active against Pseudomonas aeruginosa: in vitro properties
Antimicrob Agents Chemother 1975 Aug;8(2):132-8.PMID:810076DOI:10.1128/AAC.8.2.132.
Pipemidic acid, 8-ethyl-5,8-dihydro-5-oxo-2-(1-piperazinyl)-pyrido [2,3-d]pyrimidine-6-carboxylic acid, is a new derivative of piromidic acid. It is active against gram-negative bacteria including Pseudomonas aeruginosa as well as some gram-positive bacteria. Its potency is generally greater than that of piromidic acid and nalidixic acid. Cross-resistance is not observed between Pipemidic acid and various antibiotics, and most of bacteria resistant to piromidic acid and nalidixic acid are moderately susceptible to Pipemidic acid. The activity of Pipemidic acid is scarcely affected by the addition of serum, sodium cholate, or change of medium pH, but is subject to the influence of inoculum size. Its action is bactericidal above minimal inhibitory concentrations.
Synthesis and in vitro antimicrobial activity screening of new Pipemidic acid derivatives
Arch Pharm Res 2018 Jun;41(6):633-645.PMID:29619676DOI:10.1007/s12272-018-1025-3.
This article describes the synthesis and antimicrobial activity evaluation of new Pipemidic acid derivatives. New compounds were obtained on the basis of Mannich reaction of 4,5-disubstituted 1,2,4-triazole-3-thiones with Pipemidic acid. Antimicrobial tests revealed high antibacterial activity of obtained derivatives. Gram-negative rods belonging to Enterobacteriaceae family were particularly most sensitive to new Pipemidic acid derivatives. Synthesized compounds exhibited very strong activity towards Proteus mirabilis ATCC 12453, Salmonella typhimurium ATCC 14028 and Escherichia coli ATCC 25922. The minimum inhibitory concentrations of new Pipemidic acid derivatives which inhibited the growth of these bacteria were 0.98-7.81 µg/ml, 0.98-7.81 µg/ml and 0.98-3.91 µg/ml, respectively. The antibacterial activity of newly synthesized Pipemidic acid derivatives in many cases was far better than the activity of substances used as positive controls (nitrofurantoin, cefuroxime, ampicillin and Pipemidic acid).
Metabolites of Pipemidic acid in human urine
Xenobiotica 1980 Jan;10(1):37-46.PMID:7385914DOI:10.3109/00498258009033729.
1. The urine of men dosed orally with Pipemidic acid, contained the metabolites acetylpipemidic, formylpipemidic and oxopipemidic acids together with unchanged Pipemidic acid. 2. Each metabolite was equivalent to less than 2% of the unchanged Pipemidic acid present in human urine. 3. All metabolites showed a similar antibacterial spectrum to Pipemidic acid, but their potency was about 10 times lower than that of Pipemidic acid. The acute toxicity of the metabolites in mice was as low as the parent compound. 4. These results indicate that the role of the metabolites in the clinical efficacy and toxicity of the drug is likely to be small.